Project Grant F32AI181343
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $175,428 to The Trustees of the University of Pennsylvania to investigate the mechanisms and potential therapeutic targets for "Long COVID". The key objectives are to: 1) Determine how SARS-CoV-2-specific CD8 T cells respond to viral reservoirs in Long COVID patients, 2) Assess whether therapies that suppress SARS-CoV-2 replication...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $754,729 to the University of Pittsburgh to investigate the mechanisms by which respiratory viral infections, including COVID-19, can lead to persistent lung inflammation and damage. The research aims to understand how viral antigen persistence in pulmonary endothelial cells drives chronic activation of CD8+ T cells, leading to long-term pulmonary sequelae. The...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $107,995 to investigate the role of T cells in promoting post-acute memory deficits after COVID-19 infection in mice. The funding supports the use of a recently developed mouse model to study how systemic inflammation promotes the recruitment of antigen-specific T cells to the central nervous system after SARS-CoV-2 infection, and how these T...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the immunological mechanisms and functional potential of memory-phenotype CD8+ T cells in the context of infection and cancer. The $108,512 award, made on August 25, 2025, will enable researchers at the University of Chicago to investigate how these CD8+ T cells differentiate and acquire unique...
- The University of California, Davis was awarded a $808,672 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to conduct multi-parametric total-body positron emission tomography (PET) imaging to investigate the immune activation and systemic manifestations of post-acute sequelae of SARS-CoV-2 (PASC) infection. The 4-year project aims to develop and validate a kinetic model for the 18F-ARAG radiotracer, which has...
- This $162,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research to investigate the mechanisms that maintain the longevity and functional diversity of memory CD8+ T cells in both circulating and tissue-resident populations. The research aims to elucidate how these memory T cell subsets are regulated by cytokines during homeostasis and in response to...
- This $534,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the role of antigen location, peptide:MHCII complex density, and complex half-life as drivers of CD4+ T cell differentiation. The research, conducted by the Children's Hospital of Philadelphia, aims to provide clarity on how the strength of "Signal 1" (antigen...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $190,058 to the University of Massachusetts Medical School to investigate the role of the ADAM9 protein in the immune response to SARS-CoV-2 infection. The goal is to define how ADAM9 impacts the immunopathogenesis of severe COVID-19 and its effects on acute lung injury. The research will build on the grantee's preliminary findings...
- This Project Grant award, totaling $913,012 and effective from August 22, 2025 to July 31, 2030, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research at the University of California, San Francisco (UCSF) to assess the mechanistic basis for the increased prevalence of "Long COVID" or post-acute sequelae of COVID-19 in women compared to men. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $639,084 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research to elucidate the functional heterogeneity of naive CD8 T cells, the precursors of effector and memory T cells that are critical for immune responses against pathogens and cancer. The 5-year project aims to provide a deeper understanding of...
ELUCIDATING THE LINEAGE DYNAMICS OF OPTIMAL HUMAN CD8 T CELL RESPONSES TO SARS-COV-2 AND HOW CD8 T CELL HOMEOSTASIS IS ALTERED IN LONG COVID - PROJECT SUMMARY/ABSTRACT CD8 T CELLS ARE CRITICAL TO THE ADAPTIVE IMMUNE RESPONSE TO VIRAL PATHOGENS. WHEN NEUTRALIZING ANTIBODIES ARE INSUFFICIENT TO PREVENT VIRAL INFECTION OUTRIGHT, VIRUS-SPECIFIC MEMORY CD8 T CELLS CAN RAPIDLY KILL INFECTED CELLS AND LIMIT THE SEVERITY OF INFECTION. THIS HAS RECENTLY BEEN IDENTIFIED AS A POTENTIALLY KEY MECHANISM BY WHICH COVID- 19 DISEASE SEVERITY IS REDUCED IN VACCINATED INDIVIDUALS. MEMORY CD8 T CELLS ARE FUNCTIONALLY HETEROGENEOUS WITHIN AND BETWEEN INDIVIDUALS, WITH SOME CELLS MORE CAPABLE OF EFFECTIVELY RESPONDING DURING VIRAL INFECTION. IN THE WORST CASES, DYSFUNCTIONAL CD8 T CELL RESPONSES OR ONGOING RESPONSES TO CHRONIC VIRAL INFECTIONS COULD CAUSE PERSISTENT AND DEBILITATING SYMPTOMS, AS MAY BE THE CASE IN LONG COVID. OUR UNDERSTANDING OF THE DYNAMICS OF HUMAN CD8 T CELL DIFFERENTIATION REMAINS INCOMPLETE, INCLUDING WHY INDIVIDUALS GENERATE FUNCTIONALLY DIFFERENT RESPONSES TO AN IDENTICAL ANTIGEN. DEVELOPING EFFECTIVE VACCINES WILL REQUIRE AN UNDERSTANDING OF SHARED MOLECULAR PROGRAMS THAT CAN LEAD TO POTENT EFFECTOR RESPONSES ACROSS A RANGE OF INDIVIDUAL IMMUNE LANDSCAPES AND CD8 T CELL IDENTITIES. TWO KEY GAPS IN KNOWLEDGE IMPAIR OUR ABILITY TO FULLY LEVERAGE THE POTENTIAL OF T CELLS IN VACCINES. FIRST, LITTLE IS KNOWN ABOUT THE LINEAGES THAT PRODUCE FUNCTIONALLY DISTINCT T CELLS IN HUMANS AND WHAT FACTORS PROMOTE DIFFERENT LINEAGES. SECOND, IT IS UNCLEAR WHICH CD8 T CELL STATES RETAIN THE GREATEST CAPACITY TO MOUNT A POTENT EFFECTOR RESPONSE TO COMBAT INFECTION. THEREFORE, THERE IS AN URGENT NEED TO DEFINE HUMAN MEMORY CD8 T CELL DIFFERENTIATION TRAJECTORIES, HOW THEY IMPACT FUTURE RESPONSES TO VIRAL PATHOGENS, AND HOW THEY MAY BE DYSREGULATED IN CASES WHERE SYMPTOMS FAIL TO RESOLVE, SUCH AS LONG COVID. WE WILL ADDRESS THIS NEED BY TESTING THREE WORKING HYPOTHESES: FIRST, THAT T CELL CLONES DIFFERENTIATE DOWN LINEAGES WITH DISTINCT FUNCTIONAL CAPACITIES; SECOND, THAT EPIGENETIC FEATURES LEAVE SOME LINEAGES POISED TO MOUNT MORE POTENT RESPONSES; AND THIRD, THAT THE IMMUNE LANDSCAPE INFLUENCES CD8 T CELL DIFFERENTIATION AND FUNCTIONALITY, WITH MULTIPLE CLASSES OF IMMUNE DYSREGULATION DRIVING LONG COVID PATHOLOGY. IN AIMS 1-2, WE WILL USE CUSTOM HLA- I/PEPTIDE TETRAMERS TO SORT RARE SPIKE-SPECIFIC CD8 T CELLS FROM 5 INDIVIDUALS AT EACH OF A LONGITUDINAL SERIES OF MEMORY AND ACUTE RESPONDING TIME POINTS. WE WILL THEN PERFORM TWO CUTTING-EDGE SINGLE-CELL SEQUENCING APPROACHES THAT USE T CELL RECEPTOR AND MITOCHONDRIAL VARIANT SEQUENCES TO DEFINE T CELL CLONES AND TRACK THE DIFFERENTIATION OF THESE CLONES OVER TIME WHILE ASSESSING CELL STATES BY MRNA EXPRESSION, PROTEIN EXPRESSION, AND CHROMATIN ACCESSIBILITY. AIM 3 WILL USE A SYSTEMS IMMUNOLOGY APPROACH IN HEALTHY VACCINEES AND LONG COVID PATIENTS TO IDENTIFY FEATURES OF THE IMMUNE LANDSCAPE THAT CORRELATE WITH OPTIMAL, SUB-OPTIMAL, AND DYSREGULATED CD8 T CELL RESPONSES. COLLECTIVELY, THESE STUDIES WILL EVALUATE MULTIPLE POSSIBLE CAUSES OF LONG COVID AND WILL DEFINE THE CD8 T CELL DIFFERENTIATION LINEAGES THAT PRODUCE OPTIMAL RESPONSES, PROVIDING A BLUEPRINT FOR IMPROVED VACCINES TO REDUCE SEVERE DISEASE CAUSED BY SARS-COV-2, INFLUENZA, AND OTHER VIRUSES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $83.2k | 5/28/25 | ||
| Not listed | $5.0k | 5/16/24 | ||
| Not listed | $5.0k | 5/16/24 | ||
| Not listed | $0 | 4/5/24 | ||
| Not listed | $71.8k | 4/5/24 |